



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Pia Isomäki**

Organisation/Company: Tampere University Hospital

Country: Finland

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
05/2022-05/2022	Galapagos	filgotinib (Jyseleca)	rheumatoid arthritis
11/2021-(current)	ViforPharma	Avacopan	ANCA-associated vasculitis
02/2015-11/2019	Pfizer	tofacitinib (Xeljanz)	rheumatoid arthritis, psoriatic arthritis
05/2017-10/2019	Roche	tocilizumab (Roactemra)	giant cell arteritis
11/2016-12/2019	Eli Lilly	baricitinib (Olumiant)	rheumatoid arthritis
11/2017-09/2019	AbbVie	upadacitinib (Rinvoq)	rheumatoid arthritis

2.4 Financial interests

Classified as public by the European Medicines Agency

Company	Financial Interest
Pfizer	Honoraria for acting as a chair in educational events
Abbvie	Honorarium for acting as a panelist in an educational event

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

Principal investigator of an investigator-initiated clinical trial 'TofaSTAT', studying the effects of tofacitinib on JAK-STAT signal transduction pathways in patients with rheumatoid arthritis. A grant for the study was obtained from Pfizer. Study ended in 2020.

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential

Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Pia Isomäki
Date:	2022-09-12

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template